Click on the links or scroll down the page for information about work currently in progress by category. Please note that information summarised on this page is subject to change.
We produce prescribing guidance and other medicines resources to help patients and healthcare professionals in Wales make sure that medicines are used effectively and appropriately. When we produce these resources, we think it's important that people who might be affected by them have a chance to tell us their views.
We ask patients and carers, patient organisations, prescribers and other healthcare professionals to comment on the resources we're developing. We'd like your views on the resources we're currently working on, listed below. You don't need to comment on the whole document; only on parts that seem relevant to you.
|
We don't have any consultations open at the moment but please check back here regularly for updates. |
Patients, carers and patient organisations - please see our New medicines needing your views page for answers to some questions you might have about making a submission.
Clinical experts - please see our Clinical expert opinion for medicine appraisals page for background information.
We'd like to receive your submission before the stated deadline (so we can prepare the meeting papers). But we'll still try to include any that arrive late.
|
Medicine name: brivaracetam (Briviact®) Reference number: 4614 Indication: Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in children from 2 years of age < 4 years of age with epilepsy Patient and carer submission: Download form or submit online Patient organisation submission: Download form or submit online Clinical experts submission: Download form AWMSG meeting date: TBC |
|
Medicine name: lacosamide (Vimpat®) Reference number: 4698 Indication: Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in children from 2 years of age < 4 years of age with epilepsy Patient and carer submission: Download form or submit online Patient organisation submission: Download form or submit online Clinical experts submission: Download form AWMSG meeting date: TBC |
|
Medicine name: rituximab (MabThera®) Reference number: 3192 Indication: For the treatment of moderate to severe pemphigus vulgaris Patient and carer submission: Download form or submit online Patient organisation submission: Download form or submit online Clinical experts submission: Download form Submission deadline: 05/05/2022 AWMSG meeting date: 14/09/2022 |
|
Medicine name: bedaquiline (Sirturo®) Reference number: 4860 Indication: For use as part of an appropriate combination regimen for pulmonary multidrug‑resistant tuberculosis (MDR‑TB) in paediatric patients (5 years to less than 12 years of age and weighing at least 15 kg) when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Patient and carer submission: Download form or submit online Patient organisation submission: Download form or submit online Clinical experts submission: Download form AWMSG meeting date: TBC |
|
Medicine name: dupilumab (Dupixent®) Reference number: 4017 Indication: Indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO) who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment Patient and carer submission: Download form or submit online Patient organisation submission: Download form or submit online Clinical experts submission: Download form AWMSG meeting date: TBC |
|
Medicine name: bevacizumab (Avastin®) Reference number: 5044 Indication: In combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix. Patient and carer submission: Download form or submit online Patient organisation submission: Download form or submit online Clinical experts submission: Download form Submission deadline: TBC AWMSG meeting date: 15/06/2022 |
|
Medicine name: ambrisentan (Volibris®) Reference number: 4819 Indication: Treatment of PAH in adolescents and children (aged 8 to less than 18 years) of WHO Functional Class (FC) II to III including use in combination treatment. Efficacy has been shown in IPAH, familial, corrected congenital and in PAH associated with connective tissue disease. Patient and carer submission: Download form or submit online Patient organisation submission: Download form or submit online Clinical experts submission: Download form AWMSG meeting date: TBC |
|
Medicine name: hydrocortisone MR (Efmody®) Reference number: 3017 Indication: Treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults. Patient and carer submission: Download form or submit online Patient organisation submission: Download form or submit online Clinical experts submission: Download form Submission deadline: 15/01/2022 AWMSG meeting date: TBC |
|
Title: Care home medicines optimisation toolkit Status: Consultation completed Remit: A suite of guidance documents, tools and useful resources, in one place, intended as an easy-access resource library that can be used by staff working in care homes. Estimated publication date: March-May 2022 |
|
Title: All Wales chronic pain resources Status: Consultation completed Remit: Guidelines and resources developed to provide evidence based, prudently-driven guidance for the pharmacological management of chronic pain in Wales. In addition, quick reference guides, patient information leaflets, audit resources and educational materials will also be developed. Estimated publication date: March-May 2022 |
|
Title: Value based prescribing Status: Consultation completed Remit: This paper sets out the strategic approach for the value based prescribing programme, providing an overview to the background and a structure for the proposed work to progress. Also provided is an initial therapeutic area proposed for inclusion within the programme; biological medicines for severe uncontrolled asthma. Estimated publication date: March-May 2022 |
|
Title: All Wales Guidance for Prescribing Intervals (2022 update) Status: Consultation completed Remit: This document is an update to the 2013 All Wales Review and Guidance for Prescribing Intervals. The guidance stated that a 28-day prescribing interval was broadly recommended for repeat prescribing. A Welsh Government commissioned review of dispensing volumes in community pharmacies across Wales, undertaken by the Welsh Institute for Health and Social Care (WIHSC) concluded that, on balance, there would be benefit to patients, GP practices and community pharmacies if prescribing intervals were extended. Estimated publication date: July-September 2022 |
|
Title: Polypharmacy – guidance for prescribing (2022 update) Status: Consultation anticipated May-June 2022 Remit: This will update and replace the existing ‘Polypharmacy: Guidance for prescribing’ document. The intention of this revision is to put more of an elderly care emphasis within the document and concentrate on the groups of medicines that require review in the elderly population Estimated publication date: September-November 2022 |
|
Title: Understanding unlicensed medicines Status: Consultation anticipated September-October 2022 Remit: This will provide guidance for prescribers across primary and secondary care settings, including clarification around what the different types of unlicensed medicines are, understanding responsibilities throughout the different stages of the prescribing journey and key steps to be taken when prescribing unlicensed medicines and transferring care of relevant patients. |
|
One Wales Medicine new assessment Medicine name: vonicog alfa (Veyvondi®) Reference number: OW19 Indication: Treatment of bleeding during surgery in paediatric patients with Von Willebrand disease. Patient organisation/patient/carer submission: Submit your response by email to awttc@wales.nhs.uk Clinical experts submission: Submit your response by email to awttc@wales.nhs.uk Submission deadline: 05/08/2022 OWMAG date: September 2022 |
|
One Wales Medicine review Medicine name: rituximab Reference number: OW10 Indication: Treatment of adults and children with pemphigus (excluding pemphigus vulgaris) after failure of first-line treatments, including steroids and steroid-sparing treatments, and after failure of third-line treatments for pemphigoid disease, including steroids and steroid-sparing treatments OWMAG date: March 2022 |
|
One Wales Medicine review Medicine name: mepolizumab (Nucala®) Reference number: OW15 Indication: Treatment of chronic eosinophilic pneumonia OWMAG date: March 2022 |
|
Title: AWMSG annual report 2021-2022 Summary: Review of the activities and achievements of the All Wales Medicine Strategy Group (AWMSG) between April 2021 and March 2022. Estimated publication date: September 2022 |
|
Title: IPFR annual report 2021-2022 Summary: Review of Individual Patient Funding Request activity in Wales between April 2021 and March 2022. Estimated publication date: September 2022 |